CM313 not checked

Keymed Biosciences Co.Ltd

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
6 active
10 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“CM313 600mg(4ml)/vial. Subcutaneous injection 1200mg. The first 5 doses were administered weekly, followed by every two weeks, a total of 14 doses.”In the company’s words, NCT06791772 on ClinicalTrials.gov
Tested for
Multiple Myeloma (MM), Primary Immune Thrombocytopenia, Systemic Lupus Erythematosus, IgA Nephropathy, Platelet Transfusion Refractoriness, Aplastic Anemia
Main trialPhase 3
“This study consists of two parts. The purpose of Part 1 is to evaluate the safety and tolerability of CM336+CM313 combination therapy in participants with relapsed or refractory multiple myeloma (RRMM). Part 2 is to compare the efficacy of CM336 + CM313 (Group A) with Daratumumab + Pomalidomide +Dexamethasone (DPd) (Group B) in RRMM patients.”In the company’s words, NCT07910903 on ClinicalTrials.gov

Other drugs for Multiple Myeloma (MM)

All 133 drugs for Multiple Myeloma (MM)

Coming up4

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials10

TrialPhaseCompletesWhat it tests
Phase 3Not yet recruiting May 2030 Study of CM336+CM313 Combination Therapy in Patients With Relapsed or Refractory Multiple Myeloma
Phase 2Active, not recruiting 30 Dec 2025 Study of CM313 (SC) Injection in Subjects With Primary Immune Thrombocytopenia (ITP)
Phase 2Not yet recruiting Oct 2026 Study of CM313(SC) Injection in Systemic Lupus Erythematosus(SLE)
Phase 2Not yet recruiting Mar 2027 Study of CM313 in Subject With IgA Nephropathy
Phase 1/2Recruiting 16 Nov 2027 Study of CM313(SC) Injection in Subjects With Platelet Transfusion Refractoriness
Phase 1/2Not yet recruiting Dec 2027 Study of CM313(SC) Injection in Subjects With Relapsed/Refractory Aplastic Anemia
Phase 1/2Unknown 30 Oct 2023 A Study of CM313 Injection in Subjects With Systemic Lupus Erythematosus
Phase 1/2Unknown 28 Feb 2026 A Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma
Phase 1Unknown Jan 2023 Dose Escalation and Expansion Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma and Lymphoma
Phase 1Unknown 30 Apr 2025 Study of CM313 in Healthy Subjects
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow CM313

Following is part of Solo: you see every change to CM313 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in